Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience.

Détails

ID Serval
serval:BIB_867DFDC10223
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience.
Périodique
Radiotherapy and oncology
Auteur(s)
Atalar B., Ozsahin M., Call J., Napieralska A., Kamer S., Villa S., Erpolat P., Negretti L., Lassen-Ramshad Y., Onal C., Akyurek S., Ugurluer G., Baumert B.G., Servagi-Vernat S., Miller R.C., Ozyar E., Sio T.T.
ISSN
1879-0887 (Electronic)
ISSN-L
0167-8140
Statut éditorial
Publié
Date de publication
04/2018
Peer-reviewed
Oui
Volume
127
Numéro
1
Pages
96-102
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Résumé
The optimal treatment for adults with newly diagnosed medulloblastoma (MB) has not been defined. We report a large series of cases from the Rare Cancer Network.
Thirteen institutions enrolled 206 MB patients who underwent postoperative radiotherapy (RT) between 1976 and 2014. Log-rank univariate and Cox-modeled multivariate analyses were used to analyze data collected.
Median patient age was 29 years; follow-up was 31 months. All patients had the tumor resected; surgery was complete in 140 (68%) patients. Postoperative RT was given in 202 (98%) patients, and 94% received craniospinal irradiation (CSI) and, usually, a posterior fossa boost. Ninety-eight (48%) patients had chemotherapy, mostly cisplatin and vincristine-based. The 10-year local control, overall survival, and disease-free survival rates were 46%, 51%, and 38%, respectively. In multivariate analyses, Karnofsky Performance Status (KPS) ≥80 and CSI were significant for disease-free and overall survival (P ≤ .04 for all); receiving chemotherapy and KPS ≥80 correlated with better local-control rates.
Patients with high KPS who received CSI had better rates of disease-free and overall survival. Chemotherapy was associated with better local control. These results may serve as a benchmark for future studies designed to improve outcomes for adults with medulloblastoma.
Mots-clé
Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cerebellar Neoplasms/mortality, Cerebellar Neoplasms/pathology, Cerebellar Neoplasms/surgery, Cerebellar Neoplasms/therapy, Chemoradiotherapy, Adjuvant, Cisplatin/administration & dosage, Craniospinal Irradiation, Disease-Free Survival, Europe/epidemiology, Female, Humans, Male, Medulloblastoma/mortality, Medulloblastoma/pathology, Medulloblastoma/surgery, Medulloblastoma/therapy, Middle Aged, Multivariate Analysis, Prognosis, Retrospective Studies, Treatment Outcome, United States/epidemiology, Vincristine/administration & dosage, Young Adult, Adult medulloblastoma, Chemotherapy, Craniospinal, Multimodality, Radiotherapy, Rare Cancer Network (RCN)
Pubmed
Web of science
Création de la notice
01/02/2018 20:09
Dernière modification de la notice
20/08/2019 14:45
Données d'usage